Related references
Note: Only part of the references are listed.Neutrophils in autoimmunity: when the hero becomes the villain
Samal Bissenova et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review
Josefien W. Hommes et al.
FRONTIERS IN ONCOLOGY (2021)
Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis
Mitchell S. von Itzstein et al.
CLINICAL CHEMISTRY (2020)
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Xiao-Hui Jia et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
Rik J. Verheijden et al.
ESMO OPEN (2020)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The prognostic value of red blood cell distribution width in patients with suspected infection in the emergency department
Jan Willem Uffen et al.
BMC EMERGENCY MEDICINE (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease
Daniel Kofink et al.
PLOS ONE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Hematological Parameters Improve Prediction of Mortality and Secondary Adverse Events in Coronary Angiography Patients A Longitudinal Cohort Study
Crystel M. Gijsberts et al.
MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
Ninh M. La-Beck et al.
PHARMACOTHERAPY (2015)
Computationally efficient confidence intervals for cross-validated area under the ROC curve estimates
Erin LeDell et al.
ELECTRONIC JOURNAL OF STATISTICS (2015)
Calibration Belt for Quality-of-Care Assessment Based on Dichotomous Outcomes
Stefano Finazzi et al.
PLOS ONE (2011)
Decision curve analysis: A novel method for evaluating prediction models
Andrew J. Vickers et al.
MEDICAL DECISION MAKING (2006)
A protocol for building and evaluating predictors of disease state based on microarray data
LFA Wessels et al.
BIOINFORMATICS (2005)
Share Paper
